<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012457</article-id><article-id pub-id-type="publisher-id">ACM-39261</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_78458747.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血脂康联合瑞舒伐他汀对动脉粥样硬化性心血管疾病患者调脂疗效的研究
  Study on the Effect of Xuezhikang Combined with Rosuvastatin on Lipid Regulation in Patients with Atherosclerotic Cardiovascular Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>丽艳</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>瞳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>利方</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>薛</surname><given-names>竺雨</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>孝兹</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>丁</surname><given-names>巍</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>雪娟</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院全科医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3039</fpage><lpage>3047</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：评估血脂康联合瑞舒伐他汀对动脉粥样硬化性心血管疾病(ASCVD)患者调脂程度、达标率及安全性的影响。方法：将符合纳排标准的ASCVD患者按随机数字表法分为血脂康组(A组)、瑞舒伐他汀组(B组)、联合用药组(C组)。在治疗前后检测血浆TC、TG、HDL-C、LDL-C，监测副反应，比较治疗前后颈动脉内膜中层厚度(IMT)、斑块积分(Crouse积分)、斑块稳定性、LDL-C达标率变化。结果：3组除HDL-C升高外，TC、TG、LDL-C均下降，C组、B组、A组降LDL-C效果依次递减(P
   <sub>A:B</sub> &lt; 0.001, P
   <sub>A:C</sub> &lt; 0.001, P
   <sub>B:C</sub> &lt; 0.001)。治疗后各组IMT、Crouse积分、斑块稳定性均较前改善，各治疗组治疗后LDL-C达标率，C组、B组、A组依次下降(P
   <sub>A:B</sub> &lt; 0.001, P
   <sub>A:C</sub> &lt; 0.001, P
   <sub>B:C</sub> = 0.002)，各治疗组安全可靠( χ
   <sup>2</sup> = 0.448, p = 0.799, p &gt; 0.05)。结论：血脂康联合瑞舒伐他汀可明显降低ASCVD患者血浆TC、TG、LDL-C，提高血浆LDL-C达标率，兼具安全性的同时稳定斑块。
    OBJECTIVE: To evaluate the effect of Xuezhikang combined with rosuvastatin on the degree, success rate and safety of lipid regulation in patients with atherosclerotic cardiovascular disease (ASCVD). MEATHODS: According to the random number table method, patients with ASCVD who meet the standard of natriuretic discharge were randomly divided into Xuezhikang group (group A), rosuvastatin group (group B) and combination group (Group C). Plasma TC, TG, HDL-C and LDL-C were measured before and after treatment, even the side effects were monitored. Compared carotid intima-media thickness (IMT), plaque score (Crouse score), plaque stability before and after treatment and the LDL-C success rate. RESULTS: Except for HDL-C increase, TC, TG and LDL-C all decreased in the 3 groups and the effects of reducing LDL-C ingroup C, group B, and group A decreased successively (P
   <sub>A:B</sub> &lt; 0.001, P
   <sub>A:C</sub> &lt; 0.001, P
   <sub>B:C</sub> &lt; 0.001). After treatment the IMT, Crouse score and plaque stability of each group were improved. The success rate of reaching the standard of LDL-C in the group C, group B and group A decreased in turn (P
   <sub>A:B</sub> &lt; 0.001, P
   <sub>A:C</sub> &lt; 0.001, P
   <sub>B:C</sub> = 0.002) and all treatment groups were safe and reliable (
   χ
   <sup>2</sup> = 0.448, p = 0.799, p &gt; 0.05). CONCLUSION: Xuezhikang combined with rosuvastatin can significantly reduce plasma TC, TG and LDL-C in patients with ASCVD, improve the success rate of LDL-C, and stabilize the plaque with safety. 
  
 
</p></abstract><kwd-group><kwd>血脂康，瑞舒伐他汀，联合用药，动脉粥样硬化性心血管疾病，调脂，疗效，安全性, Xuezhikang</kwd><kwd> Rosuvastatin</kwd><kwd> Combination Therapy</kwd><kwd> Atherosclerotic Cardiovascular Disease</kwd><kwd> Lipid Regulation</kwd><kwd> Efficacy</kwd><kwd> Safety</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：评估血脂康联合瑞舒伐他汀对动脉粥样硬化性心血管疾病(ASCVD)患者调脂程度、达标率及安全性的影响。方法：将符合纳排标准的ASCVD患者按随机数字表法分为血脂康组(A组)、瑞舒伐他汀组(B组)、联合用药组(C组)。在治疗前后检测血浆TC、TG、HDL-C、LDL-C，监测副反应，比较治疗前后颈动脉内膜中层厚度(IMT)、斑块积分(Crouse积分)、斑块稳定性、LDL-C达标率变化。结果：3组除HDL-C升高外，TC、TG、LDL-C均下降，C组、B组、A组降LDL-C效果依次递减(P<sub>A:B</sub> &lt; 0.001, P<sub>A:C</sub> &lt; 0.001, P<sub>B:C</sub> &lt; 0.001)。治疗后各组IMT、Crouse积分、斑块稳定性均较前改善，各治疗组治疗后LDL-C达标率，C组、B组、A组依次下降(P<sub>A:B</sub> &lt; 0.001, P<sub>A:C</sub> &lt; 0.001, P<sub>B:C</sub> = 0.002)，各治疗组安全可靠(c<sup>2</sup> = 0.448, p = 0.799, p &gt; 0.05)。结论：血脂康联合瑞舒伐他汀可明显降低ASCVD患者血浆TC、TG、LDL-C，提高血浆LDL-C达标率，兼具安全性的同时稳定斑块。</p></sec><sec id="s2"><title>关键词</title><p>血脂康，瑞舒伐他汀，联合用药，动脉粥样硬化性心血管疾病，调脂，疗效，安全性</p></sec><sec id="s3"><title>Study on the Effect of Xuezhikang Combined with Rosuvastatin on Lipid Regulation in Patients with Atherosclerotic Cardiovascular Disease</title><p>Liyan Zhang<sup>1*</sup>, Tong Chen<sup>2</sup>, Lifang Zhang<sup>2</sup>, Zhuyu Xue<sup>2</sup>, Xiaozi Guo<sup>2</sup>, Wei Ding<sup>2</sup>, Xuejuan Zhang<sup>2#</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of General Medicine, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/27-1571755x5_hanspub.png" /></p><p>Received: Nov. 21<sup>st</sup>, 2020; accepted: Dec. 15<sup>th</sup>, 2020; published: Dec. 22<sup>nd</sup>, 2020</p><p><img src="//html.hanspub.org/file/27-1571755x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>OBJECTIVE: To evaluate the effect of Xuezhikang combined with rosuvastatin on the degree, success rate and safety of lipid regulation in patients with atherosclerotic cardiovascular disease (ASCVD). MEATHODS: According to the random number table method, patients with ASCVD who meet the standard of natriuretic discharge were randomly divided into Xuezhikang group (group A), rosuvastatin group (group B) and combination group (Group C). Plasma TC, TG, HDL-C and LDL-C were measured before and after treatment, even the side effects were monitored. Compared carotid intima-media thickness (IMT), plaque score (Crouse score), plaque stability before and after treatment and the LDL-C success rate. RESULTS: Except for HDL-C increase, TC, TG and LDL-C all decreased in the 3 groups and the effects of reducing LDL-C ingroup C, group B, and group A decreased successively (P<sub>A:B</sub> &lt; 0.001, P<sub>A:C</sub> &lt; 0.001, P<sub>B:C</sub> &lt; 0.001). After treatment the IMT, Crouse score and plaque stability of each group were improved. The success rate of reaching the standard of LDL-C in the group C, group B and group A decreased in turn (P<sub>A:B</sub> &lt; 0.001, P<sub>A:C</sub> &lt; 0.001, P<sub>B:C</sub> = 0.002) and all treatment groups were safe and reliable (c<sup>2</sup> = 0.448, p = 0.799, p &gt; 0.05). CONCLUSION: Xuezhikang combined with rosuvastatin can significantly reduce plasma TC, TG and LDL-C in patients with ASCVD, improve the success rate of LDL-C, and stabilize the plaque with safety.</p><p>Keywords:Xuezhikang, Rosuvastatin, Combination Therapy, Atherosclerotic Cardiovascular Disease, Lipid Regulation, Efficacy, Safety</p><disp-formula id="hanspub.39261-formula19"><graphic xlink:href="//html.hanspub.org/file/27-1571755x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/27-1571755x8_hanspub.png" /> <img src="//html.hanspub.org/file/27-1571755x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 背景</title><p>动脉粥样硬化性心血管疾病(ASCVD)是全球主要的公共卫生问题，降低人们生活质量，严重危害人类健康 [<xref ref-type="bibr" rid="hanspub.39261-ref1">1</xref>]。近年来研究表明，高脂血症和动脉粥样硬化、高血压等与心脑血管疾病的发生具有密切的关系，尤其是血清低密度脂蛋白胆固醇(LDL-C)水平升高是冠心病发病的重要危险因素 [<xref ref-type="bibr" rid="hanspub.39261-ref2">2</xref>]。积极采取降脂干预措施能有效降低动脉粥样硬化进程，显著减少心血管事件的发生 [<xref ref-type="bibr" rid="hanspub.39261-ref3">3</xref>]。他汀类药物作为治疗ASCVD的基石能有效抑制体内胆固醇的合成，部分患者对他汀类药物不耐受，其治疗剂量每翻一倍，LDL-C降幅仅约增加6%，但副作用明显增加，获益减小 [<xref ref-type="bibr" rid="hanspub.39261-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref5">5</xref>]。血脂康胶囊是从红曲中发酵而来具有降脂作用的中成药 [<xref ref-type="bibr" rid="hanspub.39261-ref6">6</xref>]，此外不少研究表明血脂康具备调脂外作用，如抑制炎症反应、抑制内质网氧化应激及细胞凋亡、降低动脉僵硬度、改善心功能、改善血管内皮功能、调节血糖及胰岛素抵抗等 [<xref ref-type="bibr" rid="hanspub.39261-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref11">11</xref>]。中国冠心病二级预防研究(CCSPS) [<xref ref-type="bibr" rid="hanspub.39261-ref12">12</xref>] 表明血脂康具备降低ASCVD患者总死亡危险、冠心病死亡率和不良反应少的特点。瑞舒伐他汀是一种中高强度降脂药物，与其他他汀类药物相比，降脂作用更强，不良事件生率与同类药物相似甚至更少，是指南推荐药物 [<xref ref-type="bibr" rid="hanspub.39261-ref13">13</xref>]。目前胆固醇管理的理念已从“强化他汀”转变、升华到“强化降脂”。根据“LDL原则”，联合降脂治疗将是血脂管理的着重点 [<xref ref-type="bibr" rid="hanspub.39261-ref14">14</xref>]。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>经医院伦理委员会批准，选取2019年5月~2019~12月于青岛大学附属医院就诊的符合动脉粥样硬化性心血管疾病诊断的患者，男80例，女100例，年龄41~79岁，平均(63.49 &#177; 9.51)岁。</p></sec><sec id="s6_2"><title>2.2. 纳入标准</title><p>① 年龄18~79岁，不限制性别；② 符合2016年《中国成人血脂异常防治指南》中关于ASCVD疾病的诊断；③ 近2周未使用任何调脂药物，总胆固醇(TC)：4.40~6.47 mmol/L (170~250 mg/dl)；甘油三酯(TG) ≤ 4.52 mmol/L (400 mg/dl)；④ 各种慢性病处于稳定期，无调整药物计划；⑤ 签署知情同意书。</p></sec><sec id="s6_3"><title>2.3. 排除标准</title><p>① 纯合子家族性高胆固醇血症或家族性异常脂蛋白血症；② 已知对他汀类降脂药有过敏史或严重不良反应史；③ 谷丙转氨酶(ALT)和/或谷草转氨酶(AST) ≥ 正常上限(ULN)的3倍；肌酐(CREA) ≥ 1.5倍ULN；④ 未经控制的重度高血压患者；⑤ 甲状腺功能低下；⑥ 滥用酒精和(或)药物史；⑦ 使用其他调脂药物；⑧ 不能服从改变生活方式。</p></sec><sec id="s6_4"><title>2.4. 研究方法</title><p>符合纳排标准的研究对象按随机数字表法入血脂康组(A组)、瑞舒伐他汀组(B组)、联合用药组(C组)，在改变生活方式(低盐、低脂饮食，戒烟，每周慢走3~5次，每次30分钟等)的基础上加用口服降脂药物，血脂康组：血脂康0.3 g/粒，一次2粒，一日2次；瑞舒伐他汀组：瑞舒伐他汀10 mg/片，一次1片，每晚1次；联合用药组：瑞舒伐他汀10 mg/片，一次半片，每晚1次+血脂康胶囊0.3 g/粒，一次2粒，一日2次，连续口服6个月。</p><sec id="s6_4_1"><title>2.4.1. 血脂及其它生化指标测定</title><p>治疗前后采用全自动生化分析仪检测总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(CR)、尿素氮(UA)、肌酸激酶(CK)、肌酸激酶同工酶MB (CKMB)。测定方法：所有患者均需空腹8~12 h、坐位休息5 min后由生化室工作人员抽取外周血标本，即刻上机检验。</p></sec><sec id="s6_4_2"><title>2.4.2. 颈部血管超声检查</title><p>治疗前后应用飞利浦IU22彩色多普勒超声仪，线阵探头频率8~12 MHz，测量双侧颈总动脉起始膨大处距近心端10 mm处远侧壁的纵切长轴切面下内膜至中膜外表面的垂直距离，每侧测量3次，取双侧平均值作为颈动脉内膜中层厚度(Intima-media thickness, IMT)，IMT ≥ 1.2 mm或局限性内膜厚度超过周边内膜50%为动脉粥样斑块形成，1.0 mm ≤ IMT &lt; 1.2 mm为动脉内膜增厚，IMT &lt; 1.0 mm视为正常。双侧颈动脉各斑块最大厚度之和为Crouse积分，以评估动脉粥样硬化程度 [<xref ref-type="bibr" rid="hanspub.39261-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref16">16</xref>]。根据颈部血管斑块回声特点记录不稳定斑块及稳定斑块数量，不稳定斑块包括低回声和混合回声斑块，稳定斑块包括等回声和强回声斑块。</p></sec><sec id="s6_4_3"><title>2.4.3. LDL-C达标目标</title><p>根据2016年《中国成人血脂异常防治指南》，ASCVD患者属于极高危人群，LDL-C &lt; 1.8 mmol/L (70 mg/dl)即达标，若LDL-C基线较高不能达目标值者，LDL-C较基线降低 ≥ 50%也视为达标 [<xref ref-type="bibr" rid="hanspub.39261-ref13">13</xref>]。</p></sec><sec id="s6_4_4"><title>2.4.4. 随访事件</title><p>用药后不良反应，如胃肠胀气、食欲不振、恶心、呕吐、腹痛、腹泻，肌痛，乏力，关节肿胀，横纹肌溶解，转氨酶升高，肌酸激酶升高，咽喉痛，失眠，多梦，皮疹等。</p></sec></sec><sec id="s6_5"><title>2.5. 统计学方法</title><p>所有数据均使用SPSS 22.0软件进行分析，检验数据正态性，符合正态分布的计量资料用均数&#177;标准差( x &#175; &#177; s)表示，三组及以上数据，方差齐者采用方差分析，有显著差异者以LSD-t检验进行组间比较，组内前后比较采用配对t检验；计数资料以率或构成比表示，行c<sup>2</sup>检验，P &lt; 0.05视为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 各组患者一般资料</title><p>入选ASCVD病例186例，按随机数字表法随机分为A组61例、B组62例、C组63例，随访过程中共计6例患者退出观察，其中有2例(1.08%)出现药物不耐受自行停药、1例自行增服中药水蛭粉后出现肌酸升高(0.54%)、3例因新型冠状病毒肺炎失访(1.61%)。最终有180例患者完成随访，A组、B组、C组均为60例，3组在性别比例、BMI、年龄、高血压、冠心病、脑血管病、糖尿病史方面差异无统计学意义(P &gt; 0.05) (表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General information of enrolled patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle" >A组 n = 60</th><th align="center" valign="middle" >B组 n = 60</th><th align="center" valign="middle" >C组 n = 60</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >性别</td><td align="center" valign="middle" >男</td><td align="center" valign="middle" >22 (36.67%)</td><td align="center" valign="middle" >27 (45.00%)</td><td align="center" valign="middle" >31 (51.67%)</td><td align="center" valign="middle"  rowspan="2"  >0.253</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >38 (63.33%)</td><td align="center" valign="middle" >33 (55.00%)</td><td align="center" valign="middle" >29 (48.33%)</td></tr><tr><td align="center" valign="middle" >高血压病史</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >45 (75.00%)</td><td align="center" valign="middle" >37 (61.67%)</td><td align="center" valign="middle" >46 (76.67%)</td><td align="center" valign="middle" >0.139</td></tr><tr><td align="center" valign="middle" >冠心病史</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >51 (85.00%)</td><td align="center" valign="middle" >46 (76.67%)</td><td align="center" valign="middle" >53 (88.33%)</td><td align="center" valign="middle" >0.210</td></tr><tr><td align="center" valign="middle" >脑血管病史</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >39 (65.00%)</td><td align="center" valign="middle" >42 (70.00%)</td><td align="center" valign="middle" >40 (66.67%)</td><td align="center" valign="middle" >0.838</td></tr><tr><td align="center" valign="middle" >糖尿病史</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >18 (30.00%)</td><td align="center" valign="middle" >30 (50.00%)</td><td align="center" valign="middle" >26 (43.33%)</td><td align="center" valign="middle" >0.077</td></tr><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >24 (40.00%)</td><td align="center" valign="middle" >31 (51.67%)</td><td align="center" valign="middle" >35 (58.33%)</td><td align="center" valign="middle" >0.127</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Age (岁)</td><td align="center" valign="middle" >64.40 &#177; 8.47</td><td align="center" valign="middle" >63.45 &#177; 9.88</td><td align="center" valign="middle" >62.63 &#177; 10.17</td><td align="center" valign="middle" >0.598</td></tr><tr><td align="center" valign="middle"  colspan="2"  >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >23.86 &#177; 2.95</td><td align="center" valign="middle" >25.12 &#177; 4.01</td><td align="center" valign="middle" >24.95 &#177; 3.09</td><td align="center" valign="middle" >0.088</td></tr></tbody></table></table-wrap><p>表1. 入组患者一般资料</p><p>注：P &gt; 0.05，差异无统计学意义。Note: p &gt; 0.05, the difference was not statistically significant。</p></sec><sec id="s7_2"><title>3.2. 不同治疗组治疗血脂变化</title><p>各组治疗前后TC、TG、LDL-C下降，HDL-C升高，差异具统计学意义。治疗组组间比较显示降低TG及升高HDL-C水平差异无统计学意义，各组对TG、HDL-C的影响相当。组间对TC的比较显示C组、B组、A组降TC及LDL-C效果依次递减(表2)。</p></sec><sec id="s7_3"><title>3.3. 各治疗组前后颈动脉内膜–中层厚度与斑块总积分比较</title><p>A组、B组、C组治疗前后IMT、Crouse积分改善，差异具统计学意义。各组对IMT、Crouse积分的组间比较显示C组与B组改善IMT、Crouse积分的效果相当且优于A组(表3)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Changes of blood lipid before and after treatment in each group ( x &#175; &#177; s, mmol/L</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle"  colspan="2"  >TC</th><th align="center" valign="middle" >TG</th><th align="center" valign="middle"  colspan="2"  >LDL-C</th><th align="center" valign="middle" >HDL-C</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >A组</td><td align="center" valign="middle"  rowspan="2"  >60</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle"  colspan="2"  >5.27 &#177; 0.46</td><td align="center" valign="middle" >1.77 &#177; 0.65</td><td align="center" valign="middle"  colspan="2"  >3.31 &#177; 0.43</td><td align="center" valign="middle" >1.39 &#177; 0.50</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle"  colspan="2"  >3.84 &#177; 0.44<sup>*</sup></td><td align="center" valign="middle" >1.00 &#177; 0.31<sup>*</sup></td><td align="center" valign="middle"  colspan="2"  >1.93 &#177; 0.36<sup>*</sup></td><td align="center" valign="middle" >1.51 &#177; 0.23<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >B组</td><td align="center" valign="middle"  rowspan="2"  >60</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle"  colspan="2"  >5.41 &#177; 0.55</td><td align="center" valign="middle" >1.82 &#177; 0.91</td><td align="center" valign="middle"  colspan="2"  >3.43 &#177; 0.44</td><td align="center" valign="middle" >1.28 &#177; 0.42</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle"  colspan="2"  >3.13 &#177; 0.41<sup>*</sup></td><td align="center" valign="middle" >1.17 &#177; 0.52<sup>*</sup></td><td align="center" valign="middle"  colspan="2"  >1.62 &#177; 0.30<sup>*</sup></td><td align="center" valign="middle" >1.48 &#177; 0.28<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >C组</td><td align="center" valign="middle"  rowspan="2"  >60</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle"  colspan="2"  >5.60 &#177; 0.65</td><td align="center" valign="middle" >1.96 &#177; 0.97</td><td align="center" valign="middle"  colspan="2"  >3.47 &#177; 0.58</td><td align="center" valign="middle" >1.21 &#177; 0.33</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle"  colspan="2"  >3.05 &#177; 0.50<sup>*</sup></td><td align="center" valign="middle" >1.02 &#177; 0.30<sup>*</sup></td><td align="center" valign="middle"  colspan="2"  >1.35 &#177; 0.30<sup>*</sup></td><td align="center" valign="middle" >1.44 &#177; 0.32<sup>*</sup></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >TC</td><td align="center" valign="middle"  colspan="2"  >P<sub>A:B</sub> &lt; 0.001</td><td align="center" valign="middle"  colspan="3"  >P<sub>A</sub><sub>:</sub><sub>C</sub> &lt; 0.001</td><td align="center" valign="middle"  colspan="2"  >P<sub>B:C</sub> = 0.002</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >TG</td><td align="center" valign="middle"  colspan="2"  >P<sub>A:B</sub> = 0.430</td><td align="center" valign="middle"  colspan="3"  >P<sub>A</sub><sub>:</sub><sub>C</sub> = 0.259</td><td align="center" valign="middle"  colspan="2"  >P<sub>B:C</sub> = 0.056</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >LDL-C</td><td align="center" valign="middle"  colspan="2"  >P<sub>A:B</sub> &lt; 0.001</td><td align="center" valign="middle"  colspan="3"  >P<sub>A</sub><sub>:</sub><sub>C</sub> &lt; 0.001</td><td align="center" valign="middle"  colspan="2"  >P<sub>B:C</sub> &lt; 0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >HDL-C</td><td align="center" valign="middle"  colspan="2"  >P<sub>A:B</sub> = 0.384</td><td align="center" valign="middle"  colspan="3"  >P<sub>A</sub><sub>:</sub><sub>C</sub> = 0.198</td><td align="center" valign="middle"  colspan="2"  >P<sub>B:C</sub> = 0.675</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 各组治疗前后血脂变化情况( x &#175; &#177; s, mmol/L)</p><p>注：与本组治疗前比较，<sup>*</sup>p &lt; 0.05。Note: Compared with before treatment in the same group, <sup>*</sup>P &lt; 0.05。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of carotid intima-media thickness and total plaque score before and after treatment in each group ( x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >颈动脉内膜中层厚度(mm)</th><th align="center" valign="middle" >斑块总积分(分)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >A组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >1.17 &#177; 0.17</td><td align="center" valign="middle" >3.63 &#177; 2.22</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >1.13 &#177; 0.16</td><td align="center" valign="middle" >3.28 &#177; 2.05</td></tr><tr><td align="center" valign="middle" >t/P</td><td align="center" valign="middle" >7.60/ &lt; 0.001<sup>*</sup></td><td align="center" valign="middle" >5.59/ &lt; 0.001<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >B组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >1.18 &#177; 0.19</td><td align="center" valign="middle" >3.93 &#177; 3.16</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >1.09 &#177; 0.18</td><td align="center" valign="middle" >3.16 &#177; 2.74</td></tr><tr><td align="center" valign="middle" >t/P</td><td align="center" valign="middle" >5.79/ &lt; 0.001<sup>*</sup></td><td align="center" valign="middle" >3.97/0.001<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >C组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >1.17 &#177; 0.16</td><td align="center" valign="middle" >4.07 &#177; 3.25</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >1.06 &#177; 0.14</td><td align="center" valign="middle" >3.29 &#177; 2.73</td></tr><tr><td align="center" valign="middle" >t/P</td><td align="center" valign="middle" >9.361/ &lt; 0.001<sup>*</sup></td><td align="center" valign="middle" >5.947/ &lt; 0.001<sup>*</sup></td></tr><tr><td align="center" valign="middle"  colspan="2"  >P<sub>B:A</sub></td><td align="center" valign="middle" >3.145/0.003</td><td align="center" valign="middle" >2.026/0.047</td></tr><tr><td align="center" valign="middle"  colspan="2"  >P<sub>C:A</sub></td><td align="center" valign="middle" >4.763/ &lt; 0.001</td><td align="center" valign="middle" >2.267/0.027</td></tr><tr><td align="center" valign="middle"  colspan="2"  >P<sub>C:B</sub></td><td align="center" valign="middle" >1.625/0.111</td><td align="center" valign="middle" >0.241/0.810</td></tr></tbody></table></table-wrap><p>表3. 各组治疗前后颈动脉内膜中层厚度与斑块总积分比较( x &#175; &#177; s)</p><p>注：与本组治疗前比较，<sup>*</sup>p &lt; 0.05。Note: Compared with before treatment in the same group, <sup>*</sup>P &lt; 0.05。</p></sec><sec id="s7_4"><title>3.4. 各治疗组前后颈部血管斑块稳定性变化</title><p>各组治疗前后斑块稳定性升高(P &lt; 0.05)，组间差异无统计学意义，可认为各组稳定斑块能力相当(表4)。</p></sec><sec id="s7_5"><title>3.5. 治疗前后LDL-C达标率比较</title><p>各组治疗前LDL-C均未达标，治疗后A组达标19 (31.67%)，B组达标43 (71.67%)，C组达标56 (93.33%)。组间达标率比较，A组与B组、A组与C组P &lt; 0.001，B组与C组，P = 0.002 (p &lt; 0.017)，可见用药后C组、B组、A组LDL-C达标率依次递减(表5)。</p></sec><sec id="s7_6"><title>3.6. 各治疗组不良反应比较</title><p>A组1 (1.67%)例患者出现头晕、头痛症状。B组1 (1.67%)例出现乏力症状，1 (1.67%)例出现肝功能损伤。C组1 (1.67%)例出现CK/CKMB升高。各组间比较Χ<sup>2</sup> = 0.448、p = 0.799，p &gt; 0.05，尚可认为各治疗方案安全可靠，组间无差异(表6)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of the stability of cervical vascular plaque before and after treatment in each group [n (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >斑块数目n (个)</th><th align="center" valign="middle"  colspan="3"  >稳定性斑块</th><th align="center" valign="middle" >不稳定性斑块</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >A组</td><td align="center" valign="middle"  rowspan="2"  >216</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle"  colspan="2"  >118 (54.63%)</td><td align="center" valign="middle" >98 (45.37%)</td><td align="center" valign="middle"  rowspan="2"  >0.024<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle"  colspan="2"  >141 (65.28%)</td><td align="center" valign="middle" >75 (34.72%)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >B组</td><td align="center" valign="middle"  rowspan="2"  >228</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle"  colspan="2"  >137 (60.09%)</td><td align="center" valign="middle" >91 (39.91%)</td><td align="center" valign="middle"  rowspan="2"  >0.004<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle"  colspan="2"  >166 (72.81%)</td><td align="center" valign="middle" >62 (27.19%)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >C组</td><td align="center" valign="middle"  rowspan="2"  >234</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle"  colspan="2"  >126 (53.85%)</td><td align="center" valign="middle" >108 (46.15%)</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle"  colspan="2"  >171 (73.08%)</td><td align="center" valign="middle" >63 (26.92%)</td></tr><tr><td align="center" valign="middle"  colspan="2"   rowspan="2"  ></td><td align="center" valign="middle"  colspan="2"  >治疗前(c<sup>2</sup>, p)</td><td align="center" valign="middle"  colspan="3"  >2.143, 0.342</td></tr><tr><td align="center" valign="middle"  colspan="2"  >治疗后(c<sup>2</sup>, p)</td><td align="center" valign="middle"  colspan="3"  >4.163, 0.125</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 各组治疗前后颈部血管斑块稳定性比较[n (%)]</p><p>注：与本组治疗前比较，<sup>*</sup>p &lt; 0.05。Note: Compared with before treatment in the same group, <sup>*</sup>P &lt; 0.05。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of LDL-C standard-reaching rate in each group after treatment [n (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >达标</th><th align="center" valign="middle" >未达标</th></tr></thead><tr><td align="center" valign="middle" >A组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >19 (31.67%)</td><td align="center" valign="middle" >41 (68.33%)</td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >43 (71.67%)</td><td align="center" valign="middle" >17 (28.33%)</td></tr><tr><td align="center" valign="middle" >C组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >56 (93.33%)</td><td align="center" valign="middle" >4 (6.67%)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >c<sup>2</sup></td><td align="center" valign="middle"  colspan="2"  >52.012</td></tr><tr><td align="center" valign="middle"  colspan="2"  >p</td><td align="center" valign="middle"  colspan="2"  >&lt;0.001</td></tr><tr><td align="center" valign="middle"  colspan="2"  >P<sub>A:B</sub> (c<sup>2</sup>, p)</td><td align="center" valign="middle"  colspan="2"  >19.221, &lt;0.001</td></tr><tr><td align="center" valign="middle"  colspan="2"  >P<sub>A:C</sub> (c<sup>2</sup>, p)</td><td align="center" valign="middle"  colspan="2"  >48.676, &lt;0.001</td></tr><tr><td align="center" valign="middle"  colspan="2"  >P<sub>B:C</sub> (c<sup>2</sup>, p)</td><td align="center" valign="middle"  colspan="2"  >9.755, 0.002</td></tr></tbody></table></table-wrap><p>表5. 各组治疗后LDL-C达标情况比较[n (%)]</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Comparison of adverse reactions in each group [n (n%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >头晕、头痛</th><th align="center" valign="middle"  colspan="2"  >恶心、呕吐</th><th align="center" valign="middle" >腹痛</th><th align="center" valign="middle" >乏力</th><th align="center" valign="middle" >肌痛或CK/CKMB升高</th><th align="center" valign="middle" >肝功能受损</th><th align="center" valign="middle" >总计</th></tr></thead><tr><td align="center" valign="middle" >血脂康组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >1 (1.67%)</td><td align="center" valign="middle"  colspan="2"  >0 (0.00%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >1 (1.67%)</td></tr><tr><td align="center" valign="middle" >瑞舒伐他汀组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle"  colspan="2"  >0 (0.00%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >1 (1.67%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >1 (1.67%)</td><td align="center" valign="middle" >2 (3.33%)</td></tr><tr><td align="center" valign="middle" >联合组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle"  colspan="2"  >0 (0.00%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >1 (5.00%)</td><td align="center" valign="middle" >1 (1.67%)</td><td align="center" valign="middle" >2 (3.33%)</td></tr><tr><td align="center" valign="middle"  colspan="4"  >c<sup>2</sup></td><td align="center" valign="middle"  colspan="6"  >0.448</td></tr><tr><td align="center" valign="middle"  colspan="4"  >p</td><td align="center" valign="middle"  colspan="6"  >0.799</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表6. 各治疗组不良反应比较[n (n%)]</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>动脉粥样硬化性心血管疾病的主要危险因素为高胆固醇血症对血管内皮的持续损伤，控制低密度脂蛋白水平为降低ASCVD风险的治疗靶点。目前调脂方法主要有饮食运动控制及药物治疗2方面，他汀类药物作为降脂药物的典型代表已成为预防及治疗心血管疾病的基石。研究表明肌痛、谷丙转氨酶暂时性升高及新发糖尿病与服用他汀类药物存在因果关系，其副作用限制他汀类药物的使用，尤其是大剂量他汀在特殊人群中的使用 [<xref ref-type="bibr" rid="hanspub.39261-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref19">19</xref>]。即使有良好的他汀治疗依从性，根据不同风险等级仍有30%~70%的患者，LDL-C水平也无法达到目标值 [<xref ref-type="bibr" rid="hanspub.39261-ref20">20</xref>]。短期补充monaclinK可以改善低心血管风险的高血压及高胆固醇血症患者的血脂和凋谢模式 [<xref ref-type="bibr" rid="hanspub.39261-ref21">21</xref>]。因此西方国家将红曲发酵提取物等营养制剂作为他汀不耐受人群或大剂量他汀使用人群降脂治疗的有益补充，但不认为营养制剂可单独作为降脂药物使用 [<xref ref-type="bibr" rid="hanspub.39261-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref22">22</xref>]。血脂康是从红曲中精炼而成的生物制剂，富含monacolins物质，特别是胆固醇合成酶抑制剂(HMC-COA)，不同于西方国家，中国成人血脂异常防治指南(2016年修订版)将血脂康1.2 g/天纳入中等强度调脂药物 [<xref ref-type="bibr" rid="hanspub.39261-ref13">13</xref>]。</p><p>本研究在A组、B组、C组治疗ASCVD患者6个月后，各组TC、TG、LDL-C显著下降，C组、B组、A组降TG效果无明显差异，降TC、LDL-C效果则依次递减。不同与以往大多数研究，本研究ASCVD患者HDL上升不明显且各组间无明显差异，这与Wang TJ [<xref ref-type="bibr" rid="hanspub.39261-ref23">23</xref>] 等人在高脂血症患者红曲米(RYR)治疗的随机临床研究中各组用药后HDL有升有降相似，HDL升高不明显可能与血脂康治疗提高了miR-33a和miR-33b血浆水平，抑制细胞胆固醇输出相关 [<xref ref-type="bibr" rid="hanspub.39261-ref24">24</xref>]。在斑块获益方面，C组与B组改善IMT、Crouse积分的效果相当且优于A组，各组均能提高颈部动脉斑块稳定性，但组间无统计学差异。IBIS-4、Reversal、ASTEROID、SATURN等研究表明强化他汀治疗降低LDL-C至1.8~2.1 mmol/L (70~80 mg/dl)的同时大幅度升高HDL可以获得逆转斑块效应，这些研究的观察时间在13个月到24个月不等。ARTMAP研究及COSMOS研究时间则相对较短，为6~19个月，在常规剂量他汀治疗下也都实现了斑块的逆转 [<xref ref-type="bibr" rid="hanspub.39261-ref25">25</xref>] - [<xref ref-type="bibr" rid="hanspub.39261-ref30">30</xref>]。本研究中观察到斑块改善除与LDL-C的控制和HDL维持一定水平外，还可能与人种相关。治疗期间3组均出现不良反应，以可耐受的肝功能受损为主，其次为CK/CKMB升高，头晕、头痛，乏力，不良反应各组间无明显差异。不少研究表明 [<xref ref-type="bibr" rid="hanspub.39261-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.39261-ref32">32</xref>] 血脂康单用或血脂康联合小剂量瑞舒伐他汀疗法，具有良好的耐受性及安全性。结合本文研究进一步可见血脂康联合小剂量瑞舒伐他汀并不会显著增加患者不良反应，较为安全。</p><p>综上，小剂量瑞舒伐他汀联合血脂康可明显降低ASCVD患者除HDL以外的血脂水平，提高血浆LDL-C达标率，改善动脉硬化、稳定斑块的同时兼具安全性。</p></sec><sec id="s9"><title>文章引用</title><p>张丽艳,陈 瞳,张利方,薛竺雨,郭孝兹,丁 巍,张雪娟. 血脂康联合瑞舒伐他汀对动脉粥样硬化性心血管疾病患者调脂疗效的研究 Study on the Effect of Xuezhikang Combined with Rosuvastatin on Lipid Regulation in Patients with Atherosclerotic Cardiovascular Disease[J]. 临床医学进展, 2020, 10(12): 3039-3047. https://doi.org/10.12677/ACM.2020.1012457</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39261-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">卢青, 陶雪飞, 程标, 等. 他汀类药物对高龄动脉粥样硬化性心血管疾病患者衰弱程度的影响研究[J]. 中华老年医学杂志, 2019, 38(3): 309-311.</mixed-citation></ref><ref id="hanspub.39261-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">魏妤. 动脉粥样硬化性心血管疾病的降胆固醇治疗及进展[J]. 中国临床医生杂志, 2019, 47(4): 379-381.</mixed-citation></ref><ref id="hanspub.39261-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mahmood, S.S., Levy, D., Vasan, R.S., et al. (2014) The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective. The Lancet, 383, 999-1008.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(13)61752-3</mixed-citation></ref><ref id="hanspub.39261-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">孟晓萍, 胡大一. 坚持他汀中国剂量主旋律[J]. 医学与哲学, 2017, 38(18): 9-11.</mixed-citation></ref><ref id="hanspub.39261-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Cholesterol Treatment Trialists C, Fulcher, J., O’Connell, R., et al. (2015) Efficacy and Safety of LDL-Lowering Therapy among Men and Women: Meta-Analysis of Individual Data from 174,000 Participants in 27 Randomised Trials. The Lancet, 385, 1397-1405. &lt;br&gt;https://doi.org/10.1016/S0140-6736(14)61368-4</mixed-citation></ref><ref id="hanspub.39261-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Feng, S.J., Tang, Z.H., Wang, Y., et al. (2019) Potential Protective Effects of Red Yeast Rice in Endothelial Function against Atherosclerotic Cardiovascular Disease. Chinese Journal of Natural Medicines, 17, 50-58.  
&lt;br&gt;https://doi.org/10.1016/S1875-5364(19)30009-3</mixed-citation></ref><ref id="hanspub.39261-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L., Zhao, S.P., Cheng, Y.C., et al. (2003) Xuezhikang Decreases Serum Lipoprotein(a) and C-Reactive Protein Concentrations in Patients with Coronary Heart Disease. Clinical Chemistry, 49, 1347-1352.  
&lt;br&gt;https://doi.org/10.1373/49.8.1347</mixed-citation></ref><ref id="hanspub.39261-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, J., Xiao, T., Ye, P., et al. (2017) Xuezhikang Reduced Arterial Stiffness in Patients with Essential Hypertension: A Preliminary Study. Brazilian Journal of Medical and Biological Research, 50, e6363.  
&lt;br&gt;https://doi.org/10.1590/1414-431x20176363</mixed-citation></ref><ref id="hanspub.39261-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Z.Q., Cui, L.Q. and Wang, Y. (2007) Effect of Xuezhikang on Cardiac Function, Serum C-Reactive Protein and Blood Lipid in Patients with Chronic Heart Failure. Chinese Journal of Integrated Traditional and Western Medicine, 27, 220-222.</mixed-citation></ref><ref id="hanspub.39261-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hong, X.Z., Li, L.D. and Wu, L.M. (2007) Effects of Fenofibrate and Xuezhikang on High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease. Clinical and Experimental Pharmacology and Physiology, 34, 27-35.  
&lt;br&gt;https://doi.org/10.1111/j.1440-1681.2007.04547.x</mixed-citation></ref><ref id="hanspub.39261-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Li, M., He, Q., Chen, Y., et al. (2015) Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails. Evidence-Based Complementary and Alternative Medicine, 2015, Article ID: 468520. &lt;br&gt;https://doi.org/10.1155/2015/468520</mixed-citation></ref><ref id="hanspub.39261-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Li, J.J., Lu, Z.L., Kou, W.R., et al. (2009) Beneficial Impact of Xuezhikang on Cardiovascular Events and Mortality in Elderly Hypertensive Patients with Previous Myocardial Infarction from the China Coronary Secondary Prevention Study (CCSPS). The Journal of Clinical Pharmacology, 49, 947-956. &lt;br&gt;https://doi.org/10.1177/0091270009337509</mixed-citation></ref><ref id="hanspub.39261-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版) [J]. 中华全科医师杂志, 2017, 16(1): 15-35.</mixed-citation></ref><ref id="hanspub.39261-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">郭远林, 陈纪林. 从美国2018胆固醇管理指南看非他汀类降脂药物新证据[J]. 中国循环杂志, 2019, 34(3): 221-223.</mixed-citation></ref><ref id="hanspub.39261-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, D., Wang, Y., Chang, G., et al. (2019) DNA Hydroxymethylation Combined with Carotid Plaques as a Novel Biomarker for Coronary Atherosclerosis. Aging (Albany NY), 11, 3170-3181. &lt;br&gt;https://doi.org/10.18632/aging.101972</mixed-citation></ref><ref id="hanspub.39261-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, F.F., Gao, H.Y., Gao, Y., et al. (2018) A Correlational Study on Cerebral Microbleeds and Carotid Atherosclerosis in Patients with Ischemic Stroke. Journal of Stroke &amp; Cerebrovascular Diseases, 27, 2228-2234.  
&lt;br&gt;https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.04.009</mixed-citation></ref><ref id="hanspub.39261-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Banach, M., Patti, A.M., Giglio, R.V., et al. (2018) The Role of Nutraceuticals in Statin Intolerant Patients. Journal of the American College of Cardiology, 72, 96-118. &lt;br&gt;https://doi.org/10.1016/j.jacc.2018.04.040</mixed-citation></ref><ref id="hanspub.39261-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Banach, M., Stulc, T., Dent, R., et al. (2016) Statin Non-Adherence and Residual Cardiovascular Risk: There Is Need for Substantial Improvement. International Journal of Cardiology, 225, 184-196.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2016.09.075</mixed-citation></ref><ref id="hanspub.39261-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Rosenson, R.S., Baker, S., Banach, M., et al. (2017) Optimizing Cholesterol Treatment in Patients with Muscle Complaints. Journal of the American College of Cardiology, 70, 1290-1301. &lt;br&gt;https://doi.org/10.1016/j.jacc.2017.07.752</mixed-citation></ref><ref id="hanspub.39261-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Reiner, Z. (2010) Combined Therapy in the Treatment of Dyslipidemia. Fundamental &amp; Clinical Pharmacology, 24, 19-28. &lt;br&gt;https://doi.org/10.1111/j.1472-8206.2009.00764.x</mixed-citation></ref><ref id="hanspub.39261-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Mazza, A., Schiavon, L., Rigatelli, G., et al. (2018) The Short-Term Supplementation of Monacolin K Improves the Lipid and Metabolic Patterns of Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk. Food &amp; Function, 9, 3845-3852. &lt;br&gt;https://doi.org/10.1039/C8FO00415C</mixed-citation></ref><ref id="hanspub.39261-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kasliwal, R.R., Bansal, M., Gupta, R., et al. (2016) ESSENS Dyslipidemia: A Placebo-Controlled, Randomized Study of a Nutritional Supplement Containing Red Yeast Rice in Subjects with Newly Diagnosed Dyslipidemia. Nutrition, 32, 767-776. &lt;br&gt;https://doi.org/10.1016/j.nut.2016.01.012</mixed-citation></ref><ref id="hanspub.39261-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wang, T.J., Lien, A.S., Chen, J.L., et al. (2019) A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) against Hyperlipidemia. The American Journal of Chinese Medicine, 47, 323-335.  
&lt;br&gt;https://doi.org/10.1142/S0192415X19500150</mixed-citation></ref><ref id="hanspub.39261-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Cao, R., Bai, Y., Sun, L., et al. (2014) Xuezhikang Therapy Increases miR-33 Expression in Patients with Low HDL-C Levels. Disease Markers, 2014, Article ID: 781780. &lt;br&gt;https://doi.org/10.1155/2014/781780</mixed-citation></ref><ref id="hanspub.39261-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Räber, L., Taniwaki, M., Zaugg, S., et al. (2015) Effect of High-Intensity Stain Therapy on Atherosclerosis in Non-Infarct-Related Cornary Areries (IBIS-4): A Serial Intravascular Ultrasonography Study. European Heart Journal, 36, 490-500. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehu373</mixed-citation></ref><ref id="hanspub.39261-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., et al. (2004) Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial. JAMA, 291, 1071-1080.  
&lt;br&gt;https://doi.org/10.1001/jama.291.9.1071</mixed-citation></ref><ref id="hanspub.39261-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Nissen, S.E., Nicholls, S.J., Sipahi, I., et al. (2006) Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA, 295, 1556-1565. &lt;br&gt;https://doi.org/10.1001/jama.295.13.jpc60002</mixed-citation></ref><ref id="hanspub.39261-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Nicholls, S.J., Ballantyne, C.M., Barter, P.J., et al. (2011) Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine, 365, 2078-2087. &lt;br&gt;https://doi.org/10.1056/NEJMoa1110874</mixed-citation></ref><ref id="hanspub.39261-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lee, C.W., Kang, S.J., Ahn, J.M., et al. (2012) Comparison of Effects of Atorvastatin (20 mg) versus Rosuvastatin (10 mg) Therapy on Mild Coronary Atherosclerotic Plaques (from the ARTMAP Trial). The American Journal of Cardiology, 109, 1700-1704. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2012.01.399</mixed-citation></ref><ref id="hanspub.39261-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Takayama, T., Hiro, T., Yamagishi, M., et al. (2009) Effect of Rosuvastatin on Coronary Atheroma in Stable Coronary Artery Disease: Multicenter Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS). Circulation Journal, 73, 2110-2117.  
&lt;br&gt;https://doi.org/10.1253/circj.CJ-09-0358</mixed-citation></ref><ref id="hanspub.39261-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">冯建国, 王玉琴. 小剂量瑞舒伐他汀联合血脂康对肾动脉粥样硬化性高血压的疗效及安全性分析[J]. 健康前沿, 2019, 28(4): 205.</mixed-citation></ref><ref id="hanspub.39261-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">郑思道, 杨翠, 张成英. 血脂康胶囊治疗血脂异常的Meta分析[J]. 中国医药导报, 2019, 16(14): 51-55+78.</mixed-citation></ref></ref-list></back></article>